Get the Stockscreener App
4.61
4.30%
0.19
After Hours:
4.61
Adc Therapeutics Sa stock is traded at $4.61, with a volume of 962.49K.
It is up +4.30% in the last 24 hours and up +39.27% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
See More
Previous Close:
$4.42
Open:
$4.45
24h Volume:
962.49K
Relative Volume:
1.20
Market Cap:
$518.62M
Revenue:
$69.56M
Net Income/Loss:
$-240.05M
P/E Ratio:
-1.5627
EPS:
-2.95
Net Cash Flow:
$-121.90M
1W Performance:
+4.06%
1M Performance:
+39.27%
6M Performance:
+277.87%
1Y Performance:
+49.68%
1-Day Range:
$4.275
$4.64
1-Week Range:
$4.15
$4.74
52-Week Range:
$1.05
$4.74
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Compare ADCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
4.61 | 497.25M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
What insider trading reveals about ADC Therapeutics SA stockJuly 2025 Chart Watch & Free Reliable Trade Execution Plans - newser.com
ADC Therapeutics rises on $60M PIPE financing - MSN
ADC Therapeutics raises $60 million in private placement financing By Investing.com - Investing.com Nigeria
ADC Therapeutics Announces $60 Million Private Placement - PR Newswire
Visual analytics tools that track ADC Therapeutics SA performanceQuarterly Growth Report & Detailed Earnings Play Alerts - newser.com
Published on: 2025-10-13 01:51:42 - newser.com
Should you wait for a breakout in ADC Therapeutics SA2025 Support & Resistance & Verified Chart Pattern Trade Signals - newser.com
Published on: 2025-10-12 23:16:07 - newser.com
Using flow based indicators on ADC Therapeutics SAJuly 2025 Technicals & Fast Exit Strategy with Risk Control - newser.com
What technical models suggest about ADC Therapeutics SA’s comeback2025 Short Interest & Fast Gaining Stock Reports - newser.com
Key metrics from ADC Therapeutics SA’s quarterly dataPortfolio Update Report & Low Risk Investment Opportunities - newser.com
Risk adjusted return profile for ADC Therapeutics SA analyzedJuly 2025 EndofMonth & Verified Technical Signals - newser.com
Weiss Ratings Reiterates “Sell (D-)” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
Using R and stats models for ADC Therapeutics SA forecastingMarket Growth Summary & Safe Capital Investment Plans - newser.com
What hedge fund moves indicate for ADC Therapeutics SA Common Shares stockMarket Growth Report & Daily Market Momentum Tracking - newser.com
ADC Therapeutics SA stock daily chart insightsJuly 2025 Intraday Action & Growth Focused Entry Point Reports - newser.com
ADC Therapeutics (NYSE:ADCT) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
ADC Therapeutics SA (NYSE:ADCT) Receives $7.75 Consensus PT from Brokerages - Defense World
ADC Therapeutics SA Hits New 52-Week High of $4.67 - Markets Mojo
ADC Therapeutics SA (NYSE:ADCT) Stock Catapults 25% Though Its Price And Business Still Lag The Industry - 富途牛牛
ADC Therapeutics Gains Ground Ahead Of LOTIS-7 Expansion, LOTIS-5 Readout - RTTNews
ADC Therapeutics targets $600M–$1B peak revenue potential for ZYNLONTA amid strategic refocus and cost cuts - MSN
Analysts Offer Predictions for ADCT Q3 Earnings - Defense World
ADC Therapeutics SA Hits New 52-Week High of USD 4.31 - Markets Mojo
ADC Therapeutics (NYSE:ADCT) Sets New 52-Week HighStill a Buy? - MarketBeat
Order flow analysis tools used on ADC Therapeutics SAEntry Point & Low Drawdown Trading Strategies - newser.com
Understanding ADC Therapeutics SA’s price movementTrade Risk Assessment & Daily Technical Forecast Reports - newser.com
Analyzing recovery setups for ADC Therapeutics SA investorsMarket Risk Summary & Stepwise Trade Execution Plans - newser.com
Why analysts maintain buy rating on ADC Therapeutics SA Common Shares stock2025 Market Overview & Daily Risk Controlled Trade Plans - newser.com
ADC Therapeutics SA (NYSE:ADCT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
What is the fair value estimate for ADC Therapeutics SA Common Shares stock in 2025Take Profit & Fast Momentum Entry Tips - newser.com
Intraday pattern recognizer results for ADC Therapeutics SAPortfolio Risk Summary & Verified Entry Point Signals - newser.com
Platinum Investment Management Ltd. Cuts Stock Holdings in ADC Therapeutics SA $ADCT - MarketBeat
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PR Newswire
ADC Therapeutics SA Hits New 52-Week High of USD 4.07 - Markets Mojo
ADC Therapeutics SA (NYSE:ADCT) Held Back By Insufficient Growth Even After Shares Climb 31% - Sahm
Exit strategy if you’re trapped in ADC Therapeutics SAPrice Action & AI Forecasted Entry/Exit Points - newser.com
ADC Therapeutics Updates Strategic Focus on ZYNLONTA - TipRanks
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adc Therapeutics Sa Stock (ADCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 10% Owner |
Dec 11 '24 |
Buy |
3.04 |
100,000 |
304,500 |
13,145,712 |
| Redmile Group, LLC | 10% Owner |
Dec 04 '24 |
Sale |
2.07 |
25,352 |
52,479 |
15,566,731 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):